Oral levodopa is the gold-standard therapy for treating Parkinson's disease (PD) but after a
few years of treatment the therapeutic window narrows, and patients often experience …

Advanced Parkinson's disease is characterized by periods of poor mobility, dyskinesia and
progressive decline in functional independence of the affected person despite the …

Background Depression is a prodromic and a frequent non-motor symptom of Parkinson's
disease, associated to reduced quality of life and poor outcomes. The diagnosis of …

Background Dysphagia is common in advanced phases of Parkinson disease (PD), and is a
risk factor for aspiration pneumonia. Nonetheless, dysphagia has been poorly investigated …

Background Parkinson's disease (PD) is a neurodegenerative disorder affecting both sexes,
but differences exist between male and female in clinical manifestations, functional impact of …

Purpose Autonomic failure has a major impact on the quality of life of individuals with
Parkinson's disease (PD), especially in advanced stages of the disease …

Background Levodopa‐entacapone‐carbidopa intestinal gel (LECIG) infusion was
introduced to the Swedish market in 2019 for Parkinson's disease (PD) with motor …

Introduction. In the advanced stages of Parkinson's disease (PD), when standard drug
adjustments fail to sufficiently improve patients' quality of life, device-aided therapies (DATs) …

Introduction Carbidopa/levodopa enteral suspension (CLES) previously demonstrated
reduction in total daily OFF from baseline by over 4 hours in advanced Parkinson's disease …

Introduction Parkinson's disease patients may experience altered body image perception.
Advanced Parkinson's disease (aPD) with motor complications often requires surgical and …